ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2626

The Utility of the Patient Health Questionnaire-9 to Assess Suicide Risk in Patients with Systemic Sclerosis

Ilya Razykov1, Marie Hudson2, Murray Baron3 and Brett D. Thombs1, 1Psychiatry, McGill University, Montreal, QC, Canada, 2Jewish General Hospital, McGill University, Montreal, QC, Canada, 3Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Psychosocial factors and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Vasculitis, Crohn's and Spondylarthropathies

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Depression is common in rheumatic diseases, including systemic sclerosis (SSc). In the general population, depression is associated with suicidal ideation, attempts and completion. The Patient Health Questionnare-9 (PHQ-9) is a self-administered and easily scored measure of depression symptoms that is increasingly used in medical settings. Item 9 of the PHQ-9 has been used in several studies, including with arthritis patients, to assess the prevalence of suicidal ideation. Item 9 asks patients “How often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?” The item is ambiguous, however, because it includes both passive thoughts of death and more active ideas of self-harm. As a result, some researchers have advocated using the PHQ-8, which does not include Item 9. Thus, the objectives of this study were (1) to determine the proportion of SSc patients who responded anything other than “never” to Item 9 who endorsed active suicidal ideation in response to more direct questions during a structured clinical interview and (2) to assess the association between the PHQ-9 and the PHQ-8, which does not include Item 9.

Methods: Canadian Scleroderma Research Groups Registry patients were administered the PHQ-9 and the Composite International Diagnostic Interview (CIDI) depression module in a phone interview. Item 9 responses were compared to suicidal ideation and intent in the last year based on the CIDI. PHQ-8 scores were calculated by subtracting Item 9 scores. The association between the PHQ-9 and the PHQ-8 was computed using the Pearson correlation coefficient.

Results: Of 313 patients in the study, 30 (6.9%) screened positive for suicidal ideation on the Item 9. Of those, only 1 (3.3%) had thought about suicide in some detail as assessed by the CIDI at any time in the past year. No patients had an active suicide plan at the time of the interview. Correlation between PHQ-9 and PHQ-8 scores was r=0.998.

Conclusion:

Item 9 does not appear to be an effective suicide screen. There is currently no evidence that screening for suicidality would prevent suicidal behaviour. If researchers or clinicians do screen for suicidality, direct questions about suicide should be asked. The PHQ-8 may be a better option than the PHQ-9 for assessment of depressive symptoms in SSc patients given the high association with the PHQ-9 and the ambiguous nature of Item 9.


Disclosure:

I. Razykov,
None;

M. Hudson,
None;

M. Baron,
None;

B. D. Thombs,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-utility-of-the-patient-health-questionnaire-9-to-assess-suicide-risk-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology